Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics Statistics
Share Statistics
Adaptimmune Therapeutics has 255.94M shares outstanding. The number of shares has increased by 501.05% in one year.
| Shares Outstanding | 255.94M |
| Shares Change (YoY) | 501.05% |
| Shares Change (QoQ) | 500.14% |
| Owned by Institutions (%) | 8.11% |
| Shares Floating | 226.52M |
| Failed to Deliver (FTD) Shares | 95.68K |
| FTD / Avg. Volume | 5.64% |
Short Selling Information
The latest short interest is 4.59M, so 1.74% of the outstanding shares have been sold short.
| Short Interest | 4.59M |
| Short % of Shares Out | 1.74% |
| Short % of Float | 2.57% |
| Short Ratio (days to cover) | 1.93 |
Valuation Ratios
The PE ratio is -1.92 and the forward PE ratio is -0.77. Adaptimmune Therapeutics's PEG ratio is 0.04.
| PE Ratio | -1.92 |
| Forward PE | -0.77 |
| PS Ratio | 0.76 |
| Forward PS | 0.5 |
| PB Ratio | 11.47 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Adaptimmune Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 6.26.
| Current Ratio | 2.92 |
| Quick Ratio | 2.8 |
| Debt / Equity | 6.26 |
| Debt / EBITDA | -1.41 |
| Debt / FCF | -0.98 |
| Interest Coverage | -20.54 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $351.84K |
| Profits Per Employee | $-139.95K |
| Employee Count | 506 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | 3.58M |
| Effective Tax Rate | -5.32% |
Stock Price Statistics
The stock price has increased by -76.47% in the last 52 weeks. The beta is 2.84, so Adaptimmune Therapeutics's price volatility has been higher than the market average.
| Beta | 2.84 |
| 52-Week Price Change | -76.47% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 47.61 |
| Average Volume (20 Days) | 1.7M |
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.28.
| Revenue | 178.03M |
| Gross Profit | 177.96M |
| Operating Income | -68.76M |
| Net Income | -70.81M |
| EBITDA | -52.66M |
| EBIT | -63.89M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
The company has 91.14M in cash and 74.21M in debt, giving a net cash position of 16.93M.
| Cash & Cash Equivalents | 91.14M |
| Total Debt | 74.21M |
| Net Cash | 16.93M |
| Retained Earnings | -1.09B |
| Total Assets | 245.96M |
| Working Capital | 123.64M |
Cash Flow
In the last 12 months, operating cash flow was -73.21M and capital expenditures -886.38K, giving a free cash flow of -75.93M.
| Operating Cash Flow | -73.21M |
| Capital Expenditures | -886.38K |
| Free Cash Flow | -75.93M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 99.96%, with operating and profit margins of -38.62% and -39.78%.
| Gross Margin | 99.96% |
| Operating Margin | -38.62% |
| Pretax Margin | -37.77% |
| Profit Margin | -39.78% |
| EBITDA Margin | -29.58% |
| EBIT Margin | -38.62% |
| FCF Margin | -42.65% |
Dividends & Yields
ADAP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ADAP is $1.5, which is 435.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.5 |
| Price Target Difference | 435.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.63 |
| Piotroski F-Score | 3 |